A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study.

Conclusion Innovative cetuximab-based maintenance therapy showed a trend toward improving the prognosis of mCRC patients with RAS and BRAF wild-type, while the toxic side effects of maintenance therapy were manageable.

also in 53,322 other papers

Furthermore, while maintenance therapy appears to influence OS in patients with their primary tumor resected positively, those treated locally for metastases do not demonstrate a significant trend toward enhanced OS benefits.

also in 9,775 other papers

This indicates that patients on maintenance therapy exhibit a favorable trend in disease progression and survival outcomes, with the treatment being well tolerated.

also in 1,335 other papers